The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

Supernus Pharmaceuticals Inc (SUPN) reports robust Qelbree sales and strategic advancements, despite facing increased losses ...

Pipeline assets like Onapgo and potential acquisitions could bolster growth, but uncertainties remain, especially with SPN-820's recent trial failure. I'm downgrading SUPN stock from "Buy" to ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year ...

Discover key earnings insights from Supernus Pharmaceuticals Q1 2025 call, highlighting 26% core product growth, ONAPGO launch, and robust strategic focus.

First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR ® and Oxtellar XR ® net sales (non-GAAP) ...

First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI ® increased 16% to $30.7 million, compared to the ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 ...